Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket
Gainers
Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading.
Why This Healthcare Stock Dipped Over 75%; Here Are 73 Biggest Movers From Yesterday
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares climbed 53.2% to close at $3.14 on Wednesday. Blue Water Vaccines recently announced signing of sponsored research agreement with Cincinnati Children's Hospital Medical Center for S&P vaccine platform development.
Dow Rises 150 Points As Fed Boosts Rates By 0.75 Percentage Points
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 150 points on Wednesday.
This Asset Management Stock Is Trading Higher By More Than 45%, Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 67.8% to $3.4390. Blue Water Vaccines recently announced signing of sponsored research agreement with Cincinnati Children's Hospital Medical Center for S&P vaccine platform development.
ObsEva Announces Restructuring Including Termination Of Linzagolix License Agreement With Kissei And Company Resizing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))), a biopharmaceutical company developing novel
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
ObsEva Earlier Announced European Commission Marketing Authorization For Yselty For Treatment Of Uterine Fibroids
-Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy-
-Theramex to commercialize Yselty®;
Cantor Fitzgerald Initiates Coverage On ObsEva with Overweight Rating, Announces Price Target of $6
Cantor Fitzgerald analyst Brandon Folkes initiates coverage on ObsEva (NASDAQ:OBSV) with a Overweight rating and announces Price Target of $6.
ObsEva Announces Waiver And Amendment Agreement
bsEva SA (NASDAQ:OBSV, SIX: OBSN)))), a biopharmaceutical company developing and commercializing novel therapies for women's health, announced today that it has entered into a waiver and amendment agreement